Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -21.57% is 86% above its 4-year average of -149.79%, near the high end of its 4-year range (-932.79%–-9.03%).
As of the fiscal period ended Tuesday, June 30, 2026. 59.95% above its 12-month average of -53.86%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -21.57%.
RETURN ON EQUITY (ROE)
-21.57%
RETURN ON EQUITY (ROE) AVG TTM
-53.86%
RETURN ON EQUITY (ROE) AVG 3Y
-240.85%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+59.95%
CURRENT VS 3Y AVG
+91.04%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-36.00%
median of 392 covered companies
CURRENT VS SECTOR MEDIAN
+40.09%
vs the sector median at left
Canton Strategic Holdings Inc
Market Cap
$179.70M
Return on Equity (ROE)
-21.57%
TTM Avg
-53.86%
3Y Avg
-240.85%
5Y Avg
N/A
Market Cap
$176.96M
Return on Equity (ROE)
-7104.24%
TTM Avg
-166.54%
3Y Avg
-137.65%
5Y Avg
-112.46%
Market Cap
$184.12M
Return on Equity (ROE)
-19.01%
TTM Avg
-54.50%
3Y Avg
-75.60%
5Y Avg
-59.28%
Market Cap
$174.17M
Return on Equity (ROE)
-116.42%
TTM Avg
-18.43%
3Y Avg
-136.68%
5Y Avg
-137.61%
Market Cap
$173.04M
Return on Equity (ROE)
-215.26%
TTM Avg
-150.35%
3Y Avg
8.65%
5Y Avg
-35.35%
Market Cap
$172.99M
Return on Equity (ROE)
-44.23%
TTM Avg
-36.61%
3Y Avg
-30.86%
5Y Avg
-42.66%
Market Cap
$192.97M
Return on Equity (ROE)
-136.83%
TTM Avg
-43.45%
3Y Avg
-452.04%
5Y Avg
-306.86%
Market Cap
$162.82M
Return on Equity (ROE)
-59.40%
TTM Avg
-255.06%
3Y Avg
-160.44%
5Y Avg
-112.56%
Market Cap
$160.82M
Return on Equity (ROE)
-14.07%
TTM Avg
-16.23%
3Y Avg
-27.66%
5Y Avg
-19.01%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Canton Strategic Holdings Inc (CNTN) | $179.70M | -21.57% | -53.86% | -240.85% | N/A |
| Cue Biopharma, Inc. (CUE)vs › | $176.96M | -7104.24% | -166.54% | -137.65% | -112.46% |
| Journey Medical Corporation (DERM)vs › | $184.12M | -19.01% | -54.50% | -75.60% | -59.28% |
| Precision BioSciences, Inc. (DTIL)vs › | $174.17M | -116.42% | -18.43% | -136.68% | -137.61% |
| Coherus Oncology, Inc. (CHRS)vs › | $173.04M | -215.26% | -150.35% | 8.65% | -35.35% |
| Compass Therapeutics, Inc. (CMPX)vs › | $172.99M | -44.23% | -36.61% | -30.86% | -42.66% |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.97M | -136.83% | -43.45% | -452.04% | -306.86% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $162.82M | -59.40% | -255.06% | -160.44% | -112.56% |
| Inogen, Inc. (INGN)vs › | $160.82M | -14.07% | -16.23% | -27.66% | -19.01% |
| AN2 Therapeutics, Inc. (ANTX)vs › | $202.05M | -47.78% | -64.50% | -55.96% | -125.52% |
ROE
-21.6%
ROA
-17.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -21.57% |
| 2026-03-31 | -17.18% |
| 2025-12-31 | -9.03% |
| 2025-09-30 | -167.66% |
| 2024-12-31 | -932.79% |
| 2024-09-30 | -359.59% |
| 2024-06-30 | -132.58% |
| 2024-03-31 | -126.07% |
| 2023-12-31 | -102.06% |
| 2023-09-30 | -490.16% |
| 2023-06-30 | -290.61% |
| 2023-03-31 | -256.78% |
| 2022-12-31 | -152.84% |
| 2022-09-30 | -59.78% |
| 2022-06-30 | -32.96% |
| 2022-03-31 | -28.04% |
